Cancer Care Beyond Treatment: Understanding the Complete Patient Journey

Follow-up care is recommended after cancer treatment, including assessment of physical and emotional problems that may develop months or years later.

6. Surveillance: Monitoring Disease and Managing Fear

Surveillance aims to identify recurrence, treatment-related complications, and other health problems. Its schedule depends on the cancer type, treatment received, and individual clinical factors. However, surveillance can also become an anxiety trigger. Waiting for imaging or laboratory results may produce anticipatory fear.

Follow-up care should therefore include both medical surveillance and attention to psychological responses around surveillance.

Surveillance for recurrence and the management of psychological effects are recognised as important components of survivorship care.

7. Survivorship: Continuing Care After Active Treatment

Survivorship is broader than being declared free of active disease. It refers to the period of care that begins at cancer diagnosis and continues throughout the person's life. It focuses on maintaining physical and emotional health, managing long-term treatment effects, monitoring for recurrence, and supporting overall quality of life.

It includes:

● Physical health

● Emotional and psychological health

● Late treatment effects

● Recurrence monitoring

● Second cancer prevention

● Quality of life

● Long-term health promotion

Comprehensive cancer care therefore represents a continuum rather than a single post-treatment phase.

8. Why a Longitudinal Anxiety Framework Matters

Dr. Chirag Jain has proposed onco-anxiology as an anxiety-focused framework within psycho-oncology. The proposal has three central commitments:

● Anxiety-specific clinical targeting

● Longitudinal assessment across the cancer timeline

● Attention to cancer-specific mechanisms

The framework does not replace psycho-oncology. Instead, it proposes a more focused way to identify and manage anxiety across clinically important stages.

For researchers and oncology professionals, this approach raises important questions about screening, treatment adherence, fear of recurrence, physiological measurement, and long-term outcomes.

Conclusion